Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 2/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.34 |
| ▸ | CACNB1 | Q02641 | 3/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6521493 | 0.89 | F2 (0.37) | TP53F2CACNA1HCYP2D6BACE1 | |
| SCHEMBL3408675 | 0.87 | DRD2 (0.40) | KDM4EF2CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL3405557 | 0.87 | UTS2R (0.35) | F2CACNA2D1CACNA1BCACNB1CACNA1C | |
| Hydrochloric Acid SCHEMBL6519318 | 0.86 | DRD2 (0.39) | KDM4EF2CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL3409864 | 0.86 | F2 (0.38) | TP53F2CACNA1HCYP2D6BACE1 | |
| SCHEMBL979308 | 0.85 | CACNA2D1 (0.41) | F2CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL3404007 | 0.85 | ACKR3 (0.37) | KDM4ETP53F2CACNA2D1CACNA1B | |
| SCHEMBL3406082 | 0.85 | MEN1 (0.38) | KDM4ETP53F2CACNA2D1CACNA1B | |
| SCHEMBL975805 | 0.85 | CACNA2D1 (0.38) | KDM4EF2CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL3405538 | 0.85 | CTSD (0.39) | KDM4ETP53F2CACNA2D1CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053908-A1 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | US | claimed |
| EP-2254862-A2 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | Sanofi-Aventis (FR) | 2010-12-01 | — | — | EP | claimed |
| WO-2009118473-A2 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2009-10-01 | — | — | WO | claimed |
| US-20110053908-A1 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053908-A1 | AZETIDINE-DERIVED COMPOUNDS, PREPARATION METHOD THEREFOR AND THERAPEUTIC USE OF SAME | QDPR, NHERF1, GABRR1 | KDM4E 2514/4885TP53 2179/4885F2 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.